GSK (GSK) Stock Slides 3% Following $10.6B Nuvalent Acquisition

TLDR

Table of Contents

GSK is acquiring Nuvalent in a $10.6 billion all-cash transaction, offering $124 per share — representing a 40% premium over Monday’s closing price
Shares of GSK declined up to 3% in early London trading sessions after the acquisition announcement
Nuvalent’s primary candidates target non-small-cell lung cancer and are pending FDA regulatory decisions scheduled for late 2026
Financial projections indicate revenue contributions beginning in 2027, with positive core EPS impact expected by 2029
The pharmaceutical giant maintains its 2026 full-year forecast of 7–9% core earnings per share growth despite the transaction

GSK has struck a deal to purchase Nuvalent through an all-cash transaction valued at $10.6 billion, offering shareholders $124 per share — marking a substantial 40% premium above Monday’s market close.

GSK plc, GSK

GSK stock tumbled by as much as 3% during early London market hours following Tuesday’s acquisition announcement. Despite this decline, shares remain approximately 23% higher year-over-year.

Nuvalent’s equity had experienced headwinds throughout the current year, declining roughly 12% prior to the deal announcement, which placed its market capitalization near $7 billion.

This represents the most significant acquisition under newly appointed CEO Luke Miels, who succeeded Emma Walmsley at the beginning of 2026. It marks his second major transaction this year, coming after a $2.2 billion deal to acquire Rapt Therapeutics announced in January.

The transaction will be financed primarily through a combination of new borrowing facilities, existing debt instruments, and available cash reserves. GSK has confirmed the deal structure preserves its current credit rating.

Two Late-Stage Drugs in the Pipeline

Nuvalent’s leading drug candidates address non-small-cell lung cancer in patients carrying specific genetic mutations — alterations commonly found in individuals who have never smoked. Both compounds are advancing through late-stage clinical development and are awaiting FDA regulatory determinations later in 2026.

GSK executives believe both therapies possess blockbuster commercial potential upon regulatory approval. Additionally, the acquisition provides GSK with an enhanced platform to broaden development of its experimental antibody-drug conjugate Ris-Rez, which is currently undergoing late-stage clinical evaluation.

Nuvalent specializes in developing precision-targeted oncology treatments. Its development portfolio aligns seamlessly with Miels’ strategic vision — strengthening GSK’s late-stage cancer drug pipeline.

GSK’s oncology division expanded 43% throughout 2025 to reach just under £2 billion, though this segment still represents merely 6% of the company’s £32.7 billion aggregate revenue.

By comparison, competitor AstraZeneca derives 44% of its consolidated revenue from oncology products. GSK faces considerable ground to cover in narrowing this divide, but this transaction represents a meaningful strategic advance.

GSK’s Oncology Gap — and the AstraZeneca Shadow

GSK divested its oncology operations in 2014 through an asset exchange arrangement with Novartis. AstraZeneca pursued the opposite strategy, making substantial oncology investments under CEO Pascal Soriot’s leadership — a decision that delivered exceptional returns.

Miels previously held executive positions at AstraZeneca. His appointment was broadly interpreted as indication that GSK sought to emulate elements of that successful strategy.

The Nuvalent acquisition will not alter GSK’s 2026 annual guidance, which continues to project 7–9% core earnings per share expansion. The company anticipates low single-digit earnings per share dilution spanning 2026 through 2028.

Revenue contributions are projected to commence in 2027, with core EPS enhancement materializing in 2029. Net of acquired cash positions, GSK’s total investment is calculated at $9.4 billion.

The deal is anticipated to finalize in Q3 2026, subject to customary regulatory clearances.

Miels has articulated ambitions to exceed £40 billion in annual revenue by 2031 and reinforce the product pipeline ahead of the 2028 patent expiration facing HIV medication dolutegravir.

✨ Limited Time Offer